What’s new in breast cancer research? – July-August 2025
Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no
Cancer
How breast cancer organoids can accelerate ongoing clinical trials and mAb/ADC development under FDA’s animal-reduction roadmap
Introduction Microphysiological systems (MPS) are fast becoming a cornerstone of FDA-aligned non-clinical strategy, especially when paired
Organoid and artificial intelligence in breast cancer research
Introduction Organoid and artificial intelligence approaches are central to the FDA’s roadmap for reducing animal use
Adipose tissue and breast cancer: decoding proximal crosstalk in 3D model
Introduction Adipose tissue-breast cancer crosstalk is emerging as a key driver of tumor initiation, progression, and
3D Breast Cancer Microenvironment: From Organoids to Organ‑on‑Chip for Understanding the TME
Introduction Following our articles on how breast cancer organoids and breast‑cancer‑on‑chip platforms expand beyond conventional 2D and
2D vs 3D breast cancer models: Patient‑derived organoids elevate tumor modeling
3D breast cancer models are rapidly redefining how we investigate the world’s deadliest malignancy in women,
Breast cancer organoids as alternative to animal models
Breast cancer remains the most frequently diagnosed malignancy in women worldwide and a leading cause of
How the adipose tissue microenvironment shapes cancer therapy outcomes
The interplay between adipose tissue and therapeutic efficacy is now recognised as a major determinant of clinical
Animal Testing Landscape 2025
About this white paper Animal testing has played a crucial role in medical advancements, leading to
Scientific Poster – Adipose Tissue Organoid Model from Stromal Vascular Fraction
SCIENTIFIC POSTER — Adipose tissue organoid model from stromal vascular fraction Mathilde Cadoux, PhD; Emilie Ouanounou;
get in touch
Get the best insights about Cherry Biotech by Email
Let’s stay in touch!